Creative Biolabs offers comprehensive cellular functional selectivity panels that are integral to the therapeutic antibody and protein development processes. Our experts are proud to offer the chemokine receptor (CCR) panel screening service for exploring the therapeutic potential of CCR targets.

Introduction to GPCR

Chemokine receptors, such as the CC chemokine receptor (CCR), constitute a vital part of the G protein-coupled receptor (GPCR) family. CCRs play a pivotal role in immune system signaling and cellular communication and are primarily expressed on the surfaces of immune cells. They are responsible for the direction of cell movement (chemotaxis) toward sites of inflammation, infection, and injury. Their critical role in conditions such as cancer, autoimmune diseases, and inflammatory disorders positions them as attractive targets for therapeutic intervention. Consequently, thorough and precise screening of these receptors can significantly impact the development of targeted therapies.

Fig.1 Key chemokines induce immune cell infiltration into the solid tumor.¹

Our CCR Panel Screening Service

Creative Biolabs offers a cutting-edge CCR panel screening service, meticulously designed to advance the understanding of the agonist or antagonist activity of therapeutic agents that target CCRs. Our service includes a robust panel of functional cell-based assays that are tailored to measure the specificity and selectivity of CCR-targeting therapeutic agents more effectively during the drug development phases. Leveraging this service, researchers are empowered to assess the functional efficacy of potential therapeutic agents, thereby determining their ability to modulate CCR signaling pathways.

Features of the GPCR Panel

• Comprehensive Target Coverage: Our CCR panel covers a broad array of targets within the CCR receptor family, including but not limited to CCR1, CCR2, CCR5, CCR6, CCR7, CCR8, CCR9A, and CCR9B.
• Functional Approach: Our CCR Panel is based on functional assays, which means researchers can directly measure the pharmacological impact of a drug on its target. This functional data is crucial for understanding the therapeutic potential and safety profile of new drugs.
• Customized Panel: The panel can be customized to include assays for specific CCR receptors based on the research needs.

Advantages

• Comprehensive Target Panel
  Covers a broad range of CCR targets, including CCR1–CCR9B, enabling detailed assessment of therapeutic candidates across multiple chemokine receptors relevant to immune response and disease.
• Functional Data Output
  Utilizes cell-based functional assays to directly measure drug-induced CCR activation or inhibition, offering valuable insights into therapeutic efficacy and potential safety profiles.
• Customizable Screening Options
  Panels can be tailored to focus on specific CCRs based on research objectives, allowing researchers to streamline discovery efforts and concentrate on their most relevant targets.
• Expert Scientific Support
  Backed by a team with deep expertise in immunology and GPCR biology, ensuring high-quality data generation and project-specific guidance throughout the screening process.

Applications

• Cancer Immunotherapy Development
  Assists in evaluating CCR-targeting antibodies or proteins that modulate immune cell trafficking into tumors, supporting the development of therapies that enhance tumor infiltration.
• Autoimmune Disease Research
  Facilitates identification of CCR inhibitors or modulators that suppress immune cell migration, contributing to new treatments for rheumatoid arthritis, IBD, and multiple sclerosis.
• Inflammation Target Validation
  Supports early-stage discovery of therapeutics aimed at CCR-mediated inflammatory pathways, critical for diseases like asthma, psoriasis, and chronic inflammation.
• Infectious Disease Therapeutics
  Enables screening of agents that modulate CCRs involved in pathogen response, such as CCR5-targeted strategies for HIV, aiding in antiviral drug discovery.

At Creative Biolabs, we understand the complexities involved in therapeutic antibody and protein development. Our team of experts is dedicated to providing state-of-the-art services that leverage the latest in scientific advancements. By integrating our CCR panel screening service into your drug development pipeline, you can gain critical insights into the functional selectivity and therapeutic potential of your drug candidates. For more information about our CCR panel screening service or to discuss your specific project needs, please contact us.

Reference

1. Kohli, Karan, Venu G. Pillarisetty, and Teresa S. Kim. "Key chemokines direct migration of immune cells in solid tumors." Cancer gene therapy 29.1 (2022): 10-21. under Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use